Abstract. West Nile virus (WNV) is a flavivirus that is maintained in a bird-mosquito transmission cycle. Humans, horses and other non-avian vertebrates are usually incidental hosts. However, WNV is a neurotropic virus, which requires an efficient humoral response for the control of a neuroinvasive infection. The WNV genome encodes three structural (capsid, premembrane/membrane and envelope) and seven nonstructural proteins. Bioinformatic analysis performed on the WNV genomes detected a conserved alternative open reading frame restricted to the lineage I virus. To quickly verify the existence of this putative protein, entitled West Nile Alternative Reading Frame 4 (WARF4), we produced a prokaryotic recombinant source of WARF4 and verified its immunogenicity in vivo by analyzing 43 horse serum samples, of which 15 were positive for antibodies to WNV premembrane and envelope (prM-E) proteins. Specific antibodies to WARF4 were significantly detected in 5 out of the 15 serum samples testing positive for antibodies to prM-E WNV proteins. Our findings provide evidence of a significant antibody response to the WARF4 protein in the serum of the horse testing positive for antibodies to prM-E proteins, thus indicating that this antigen might be a potential tool for further characterization of the immune response of WNV infections in humans as well.
Introduction
Following its original isolation, West Nile virus (WNV) was implicated in sporadic outbreaks of mild viral illness in Africa, the Middle East, western Asia and Europe (1, 2) . Since 1999, the virus has emerged as a new threat to humans and mammals in the western hemisphere (3, 4) . Phylogenetic analyses reveal two distinct lineages (5): lineage I, which has a worldwide distribution and is involved in human and equine outbreaks, and lineage II, which is present in Africa's subSaharan region and is not associated with clinical manifestations in humans (6, 7) . Although several studies are in progress for a better understanding of WNV pathogenesis, the mechanisms of immunological escape of West Nile remain unclear (8) . Moreover, it is suggested that unidentified factors may be involved in the West Nile disease (9) . WNV can be transmitted to humans and can cause encephalitis, depending on age and the immunity status of the exposed individual (3). Antibody-positive blood components are less efficient transmitters of the virus than antibody-negative components, thus indicating that neutralizing antibodies are essential for the control of WNV infection in vivo and that an efficient humoral response is critical for the control of a neuroinvasive WNV infection (10, 11) .
To obtain a major number of proteins without modifying the genome size, viruses often make use of an alternative reading frame gene embedded in the mean coding strand. The existence of superimposed genes, first noted in bacteriophage φX174 (12) , is a phenomenon well characterized in viruses as well as in other organisms (13) (14) (15) . Among the flavivirdae, the use of an alternative open reading frame protein (ARFP) has been reported for hepatitis C viruses (HCV) (16) . After humans, horses constitute the majority of mammals infected with WNV (17 West Nile virus. The nucleic acids were extracted using the NucleoSpin RNA Virus Kit according to the manufacturer's instructions (Macherey-Nagel, Düren, Germany).
Cloning and espression of WARF4 protein.
The fragment of 394 bp spanning the WARF4 position 7327-7720 (accession number AF260967) was amplified in a single step RT-PCR using 5' forward oligonucleotide (gttgaggaattctttccaaacctct cccaag) and 3' reverse oligonucleotide (atgcgcggatcccagc ggcggacagcggctgg). The fragment was cloned into the expression vector pRSETC and then expressed in the BL21 Star (DE3)pLysS competent cells (Invitrogen, CA). The histagged recombinant protein (WARF4) was purified under denaturing condition with Ni-NTA Agarose resin (Qiagen, Germany). Proteins were visualized by Coomassie Blue staining.
Western blot analysis.
Approximately 200 ng of the WARF4 protein or the bacterial cell extract transformed with the plasmid vector alone was separated by SDS/PAGE and then transferred to a nitrocellulose membrane. After blocking, membranes were incubated with horse serum (1:1000) overnight at 4˚C. The 1:1000 dilution was chosen for testing as the highest serum concentration that lacked substantial background reactivity. After washing, the filters were incubated with anti-horse IgG whole-molecule peroxidase conjugate (Sigma) and developed by a chemiluminescent kit (Sigma) as previously described (18) (19) (20) . Criteria of positivity was the appearance of an immunoreactive band in the WARF4 sample, co-migrating with the one visualized by the anti-his antibody and not in the bacterial cell extract used as negative control. 
Results
In silico analysis detected six ARFs (Fig. 1) . Among the others, the ARF4 appears to be the longest (447 bp) and most conserved from the genomes, present in 88% (44/50). This novel alternative reading frame, entitled WARF4, begins from a +2 position when compared to the coding strand. This novel potential gene is embedded between the NS4b Cterminal residue and the NS5 N-terminal residue (7311-7757 bp, accession number AF260967), starting from a GGC triplet and terminating with a TAG stop codon. The WARF4 amino acid sequence does not show an apparent homology with other known protein sequences. Assuming that the initiation codon is the first in the alternative frame, the protein would contain 148 AA and shows an isoelectric point of 9.4. Bioinformatic analysis predicts a myristoylation signal in position 1 to 10 AA with a low probability of false-positive prediction. In order to prove the actual existence of the WARF4 protein, we produced a prokaryotic recombinant source of WARF4 and verified its immunogenicity in vivo by analyzing its reactivity with 43 horse serum samples by Western blotting. Among the others, 15 horse sera showed antibodies against prM-E WNV proteins, while 28 lacked reactivity to the same proteins. Criteria of positivity to WARF4 recombinant protein was the appearance of an immunoreactive band in the WARF4 sample, co-migrating with the one visualized by the anti-his antibody and not in the bacterial cell extract used as negative control. Two proteins in the WARF4 sample were detected in several horse serum samples as well by the anti-his antibody (Fig. 2) . The lower molecular weight protein might represent a degradation product of the full length WARF4 recombinant protein.
Overall, we detected serum antibodies to WARF4 recombinant purified protein in 5 out of 15 horses which simultaneously displayed antibodies against the prM-E proteins. Serum antibodies were also detected in one of 28 horses testing negative for antibodies to WNV prM-E proteins. To demonstrate the specificity of the humoral response to WARF4, a competition assay was performed (Fig. 3) . When using the highest WARF4 protein concentration as competitor, the serum reactivity disappeared thus confirming the presence of specific IgG for the WARF4 protein. A significant association was found between the presence of antibodies to prM-E and WARF4 proteins in horse serum (p<0.015) ( Table I) .
Discussion
West Nile virus, which has become endemic in North America, is a positive-sense RNA neurotropic virus (10, 11, 17) . The WNV genome encodes 3 structural (capsid, premembrane/ membrane and envelope) and 7 nonstructural proteins (10, 11, 17) . Neutralizing antibodies are essential for the control of the WNV infection (10, 11, 17) . It was demonstrated that MHC molecules can also present peptides encoded in alternate translational reading frames (21) . The general importance of out of frame proteins was highlighted for their ability to enhance immunity responses (21) . Furthermore, it was demonstrated that these alternative products may have a critical role in the pathogenesis of viral infections (22, 23) . The WNV genome has been completely sequenced, and our computer-assisted analysis indicates the presence of 6 ARFs. Among the others, alignment analysis shows that the ARF4 (entitled West Nile Alternative Reading ------------------------------------------------ a For statistical analysis, results were analyzed by a 2x2 contingency table. A significant association was found between antibodies to prM-E proteins and WARF4 protein (p<0.015).
-
Frame 4, WARF4), represents a unique feature of lineage I WNV genomes, that are often associated with clinical symptoms. In order to prove the actual existence of the WARF4 protein, we produced a prokaryotic recombinant source of WARF4 and verified its immunogenicity in vivo by analyzing its reactivity with 43 horse sera by Western blotting. The horse sera were also characterized for their reactivity to well known premembrane and envelope (prM-E) WNV proteins by a commercial ELISA kit.
Our results demonstrated a differential reactivity of the horse sera. Five serum samples displayed antibodies for both WARF4 and prM-E WNV proteins; 10 sera, testing positive for prM-E antibodies were WARF4 negative. Conversely, one serum sample lacking immunoreactivity to prM-E appeared, instead, reactive to the WARF4 recombinant protein. Our results indicate a statistically significant association between the presence of antibodies to prM-E proteins and WARF4 in the horse sera (p<0.015) ( Table I ). The reactivity of horse sera to prM-E protein but not to WARF4 might be related to the ARF4 expression level. Indeed, ARF proteins are reported to be usually less expressed compared to ORF proteins (24) . The fact that a single horse had specific antibodies to the WARF4 protein but not to the prM-E proteins might suggest cross-reactivity of antibodies with cocirculating flavivirus protein (25) or a different sensitivity of the assay used for testing the presence of antibodies.
We have not yet investigated the translation mechanisms of this novel encoded protein. A cap-dependent ribosomal scanning process is involved in WN virus translation, although a different strategy was reported for other flaviridae (26) . Since the WARF4 gene lacks an AUG codon, a potential alternative translation mechanism could take into account the ribosomal frame shift; nevertheless other non-canonical translation mechanisms cannot be excluded. At this stage it is not possible to speculate on the function of this novel protein. Furthermore, it must be highlighted that the presence of antibodies to the WARF4 protein needs to be observed in humans infected by WNV. Overall, our findings provide the evidence of an antibody response to the WARF4 protein in the serum of horse testing positive for antibodies to prM-E proteins, thus indicating that this antigen might be a potential new tool for further characterization of the immune response of WNV infections in humans as well. However, further studies are necessary to show that the WARF4 protein is produced in the context of WNV infection. On the other hand, it will be intriguing to investigate whether a potential association exists, between the evidence of a WARF4 specific immune response and the outcome of the human WNV disease. In this context, it is also suggestive that lineage II WNV genomes lacking WARF4 are not associated to human clinical disease.
